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1. Introduction
Today in the clinical practice Diabetes Mellitus (DM) has supplanted syphilis and tuberculosis
as the big masquerade. Now, from the professional view, many physicians are involved in
hard challenges, controversies concerning diabetic patients: insulin resistance, management
of the disease, diabetic pregnant women, carbohydrate disorders, diabetic foot, diabetes and
surgery, pharmacological aspects, psychological and sociological problems, new modalities of
treatment and many others and important clinical questions. Diabetes mellitus, the most
common endocrine disorder, is characterized by several metabolic abnormalities and numer‐
ous long-term complications affecting mostly the kidneys, peripheral nerves, blood vessels,
organ vision, and central nervous system; also, we must not forget that it is the main cause of
morbidity and mortality in the Western and developed countries.
Since the discovery of insulin in 1921 by Banting and Best, and McLeod, it has been employed
in the treatment of DM [1]. By the time, the manufacturing process of insulin has improved
becoming free of impurities or associated to hormonal products (glucagon, polypeptide
pancreatic, proinsulin) until obtaining purified insulin.
Insulin was obtained from a bovine source; and particularly porcine insulin differs only from
the human insulin in one aminoacid. Later in the clinical practice, biosynthetic and semi-
synthetic human insulin were introduced, having a structure identical to the native human
insulin, and, for that circumstance without antigenic power. The semi-synthetic insulin comes
from laboratory transpeptidation of porcine insulin (exchange of alanine by threonine of
aminoacid B30), while biosynthetic insulin is obtained by means of genetic recombination
process from bacterias (Escherichia coli) or yeasts. Today, biosynthetic insulin is the most
frequently used in some countries.
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On the other hand, insulin is a polypeptide hormone synthesized in the beta cells of the islets
of Langerhans of the endocrine pancreas, and it is necessary for normal metabolization of
glucose by most cells of the body. In diabetic persons the capacity of body cells to use glucose
is inhibited, thereby increasing blood sugar levels (hyperglycemia). When high levels of
glucose are present in the blood, the excess must be excreted in the urine (glycosuria). The
symptoms derived from the disease are increased urinary volume, thirst, itching, hunger,
weight loss, and weakness; in medical expression the classical findings are well known:
polyuria, polydipsia, polyphagia, slimming, and asthenia [2, 3].
Diabetes affects an estimate of 366 million people worldwide, with type 2 diabetes mellitus
(T2DM) accounting for more than 90% of the cases. Renal insufficiency is a common comor‐
bidity condition in T2DM patients with chronic kidney disease (CKD,) defined as kidney
damage or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 for > 3 months.
The kidney is both the origin and victim of elevated blood pressure. Hypertension is a
pathogenic factor that contributes to the deterioration of kidney function. Therefore, manage‐
ment of hypertension (salt reduction intake adequate diet, exercise and antihypertensive
drugs) has become the most important intervention control all modalities of chronic kidney
disease (CKD). The role of hypertension in renal disease is crucial. The aged world population
is increasing. The ageing is the most common risk factor for the development of hypertension
and diabetes, as well as CKD [4].
2. Historical evocation
Diabetes was known some millenniums before the Christian era, and it was in India where the
disease was more deeply studied during the ancient age. The first data come from the Ayurveda,
texts concerning medicine writings (sankrit texts). The word Ayurveda means knowledge or
“science life”; it has profound roots on the philosophy and Hinduistic spirituality; it was
developed between years 3000 and 500 b.C. on the valley rivers of the Indian civilization. Its
knowledge was transmitted orally from generation to generation through the verses known
as vedas. At that time some documents showed detailed information about unquenchable thirst
–polydipsia-in the diabetic patients, increased urine –polyuria-, and sugar in urine –glycosu‐
ria-. Instead of sweetened and viscous consistency of the urine, they described other symptoms
such as halitosis, digestive and respiratory disorders, somnolence, tuberculosis, and foruncu‐
losis. The autochthonous black ants indirectly helped to detect this pathology. The physicians
observed how ants and flies congregated around the urine being attracted by its taste. Based
on that circumstance, it was called honey urine. Also, they pointed out that diabetes were more
frequent in obese people, usually taking rice and sweeten food.
The majority of historians accept the papyrus form of 1862 close to the ruins of Luxor, the
ancient sacred city of Thebes. The well-known document, a roll of papyrus by two meters long
and thirty centimeters large, is a vast compendium with the totality of knowledge at the
pharaohs era like at current texts of medicine. The physician-priest recommended, as treat‐
ment, fatty of calf, beer, leaf of mint, hippopotamus’s blood and offering sacrifice to gods. The
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antiquity of this document is about 3500 years; it was acquired and analyzed by the German
Egyptologist George M. Ebers (1837-1898). It is currently kept in good conditions at the library
of the University of Leipzig. The first description of diabetes appeared in this papyrus where
polyuria was described. Celsus in the 1st century of our era established from his personal
experience the “painless polyuria with dangerous emaciation”. Areteus of Capadocia (century
II), a Greek physician named the disease diabetes; in greek, diabainein means “to pass through”,
or “running throw” which is in relation to severe diuresis favourable to final outcome; and
from Latin, mellitus (sweetened with honey). Claudius Galenus (3rdcentury) considered diabetes
as a kidney disease. Thomas Willis (1621-1675) in 1675 found in the patients the sweetness of
the urine, and William Cullen (1710-1790) proposed the term mellitus. The hereditary character
of the disease was postulated by R. Morton in his text Phthisiologia (1689). Another historical
event was made by P. Langerhans (1847-1888) when he described the pancreatic islets. Allen
(1914) with an uniqueness criteria considered diabetes as a hereditary disorder of carbohydrate
metabolism resulting in insufficient production of insulin. Since the discovery of insulin by
Frederick Grant Banting, Charles Herbert Best and John Richard MacLeod, Nobel Prizes of
Medicine in 1923, the prognosis of the disease is improving, although the prevalence still rises
progressively from 5 % at age 20 to older people > 75 years.
The Canadian physiologist Frederick Grant Banting (1891-1941) and the medical student
Charles Herbert Best (1899-1978) isolated insulin in Toronto in 1922. At that point, the new era
on the treatment of diabetes was started. The results of the work by the German internist Oskar
Minkowski (1858-1931) and Joseph von Mering (1894-1908) of removing the pancreas, led to
the conclusion that the cause of diabetes resides in the lack of internal secretion of the Lan‐
gerhans’s islets placed in the pancreas.
Many researchers have dedicated their efforts to obtain the hormone against diabetes. In 1909,
the Belgian Jean de Meyer named insulin the substance produced by the islets of Langerhans.
Particularly, the internist Georg Ludwig Zülzer (1870-1949) was able to isolate after 1903 an
effective compound. Nevertheless, two circumstances led him to abandon his work: a)
uncontrollable toxic allergic reactions; and, b) overdose impossible to recognize for the absence
of method of blood glucose determination. On July, 1921, the director of the Physiology
Institute of Toronto, John James Richard MacLeod (1876-1935) provided to the young physician
Frederick Grant Banting with a laboratory and ten dogs, and 21-year-old student Charles
Herbert Best as his assistant. Banting and Best had been working to obtain insulin from a saline
solution of triturated islets of pancreas. The extract was administered to diabetic dogs, by
intravenous injection; simultaneously Best carried out continuous determinations of sugar in
blood. This work made possible the new measuring methods that need only 0.2 ml of blood
instead of 25 ml. After this finding Banting and Best studied better and easier procedures to
obtain the hormone from cow fetus of four months. They discovered that the active substance
was better extracted with acetone instead of acidulous alcohol. The decisive experiments were
carried out between the 7 and 14th August of 1921.
After the first and successful achievements, MacLeod decided to interrupt any other investi‐
gation and focus on the insulin project: purification, control and manufacturing. The chemist
James Bertram Collip (1892-1965) was able to obtain huge amounts of insulin and to success
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to its standardization. The latter is of capital importance because overdose can produce muscle
spasm due to hypoglycemia.
Since the end of the 19thcentury, researchers have found the relationship between the pancreas
and the metabolic disease –diabetes-. Some of them pointed out that the clinical problems are
produced by the lack of a hormonal substance secreted by the endocrine pancreas or Langer‐
han’s islets, although the German Oskar Minkowski (1858-1931) and others investigators failed
to isolate this hormone. Edward Albert Sharpey-Schafer (1850-1935) coined the word “insulin”;
he considered that insulin controls the hydrocarbonate metabolism and that the absence of
insulin will be followed by hyperglycemia and an increase of glucose in urine. After that
conclusion, pancreatic extract was given to diabetic patients; but unfortunately, this attempt
was unsuccessful because the hormone was destroyed by the proteolytic enzymes. Also, the
technical procedures for blood and urine glucose determinations available were rudimentary
and with little accuracy. After numerous attempts, researchers obtained more purified insulin
to be used in the clinical practice. Insulin was used for the first time in 1922 in a 14-year-old
diabetic boy, who presented good results; it was the first publication concerning the efficacy
of insulin in humans and was published in the prestigious journal Canadian Medical Association
Journal.
One year later, in 1923, the Medicine Nobel Prize was awarded to Banting and MacLeod for
his crucial medical milestone. In 1926, Jakob Abel found the synthesis of insulin; this finding
was published in the Proceedings of the National Academy of Sciences, Washington, with the article
entitled Crystalline insulin. After that, the era of insulin was started.
As it is well known, there are two modalities of the disease: insulin dependent diabetes mellitus
or IDDM (type I) found in young people requiring daily insulin injection; although most cases
of IDDM appear before age 20, the disease can develop late in life. In these patients, the
necessary insulin is not secreted by the pancreas and hence must be managed by parenteral
way. On the other hand, Type II, non-insulin dependent diabetes mellitus (NIDDM), adult
onset diabetes, can be controlled by strict dietary restriction of carbohydrates, oral hypogly‐
cemic agents (blood-sugar-lowering) and also insulin in some particular patients. The situation
coming from sluggish pancreatic insulin secretion and concomitant tissue resistance to
secreted insulin worsens insulin secretion by the beta cells. Anyway, despite the previous
classification as juvenile or adult diabetes, either type can be observed at any age; however,
NIDDM is the most common clinical presentation found in up to 90 percent of all forms of
diabetes. The risk factors predisponing to type 2 diabetes are pointed out in table 1.
From the clinical point of view, to get a suitable control of the disease (blood glucose, glycated
hemoglobin, lipids profile, body weight, and quality of life) it is crucial to ensure successful
outcomes [table 2]. We must realize that subjects with asymptomatic, undiagnosed diabetes
not unusually develop serious complications. Despite the absence of fasting hyperglycemia
large-scale screening with glucose tolerance test should be established in many cases. Nowa‐
days, the goals of therapy with insulin or oral agents for varied circumstances is frequently
hazardous [5]. This particular point explains the urgent necessity to find better drugs (more
effective and well tolerated). The way to reach this goal is, undoubtedly, the clinical investiga‐
tion; in others words, clinical trials [6].
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Family antecedents of diabetes (parents)
Obesity (Body Mass Index BMI >25 kg/m2
Sedentarism
Race/ethnicity
Previously identified impaired fasting glucose (IFG), or impaired glucose tolerance (IGT)
Gravid diabetes mellitus (GDM)
HDL cholesterol < 35 mg/dl and/or triglyceride level > 250 mg/dl
Previous vascular disease
Acanthosis nigricans or polycistic ovary syndrome
Table 1. Risk factors predisposing to type 2 diabetes mellitus.
1. Symptoms of diabetes –polyuria, polyphagia, polydipsia, slimming or asthenia- plus random blood glucose level
200 mg/dl. Or
2. Fasting plasma glucose > 126 mg/ dl. Or
3. Two-hour plasma glucose (200 mg/dl) during an oral glucose tolerance test.
1) Random is considered at any time since the last meal
2) Fasting is defined as no food intake for previous 12 hours
3) Two-hours plasma glucose > 200 mg/dl during glucose tolerance test
Table 2. Clinical and laboratory criteria for diagnosis of diabetes mellitus
In 1912, two Boston researchers, F. G Benedict and Elliot P. Joslin, founder of the Joslin Diabetes
Center –Boston-iniciated extensive metabolic balance studies in diabetic patients whose
circulating blood glucose levels were high; they intended to control the disease by an strict
dietary restriction of carbohydrates. And now, more than a century after the creation of the
former institution, it continues the tradition of excellence recognized everywhere as a diabetes
research, treatment, and teaching center. It is focused to improve the lives of persons with
diabetes today and in the future. We now know that the excreted sugar coming from exogenous
and endogenous proteins is converted in our body by the liver into glucose. But, in spite of the
hard investigations, nowadays diabetes remains a difficult clinical problem mostly in the
Western and developed countries.
3. Personal overview
Based on this controversial clinical status and related to our conventional duty since March
1990, our group in Granada (Spain) has created a Hypertension and Lipid Unit, and during the
large interim period (twenty four years) until now, we have carried out a huge work by
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participating in several international clinical studies –more than one hundred fifty-focused
mostly on hypertension and diabetes, but also on lipid disorders and ischemic heart disease;
many of them are well recognized everywhere by prestigious publications using acronyms
titles for an easier identification of them: SYST-EUR, HYVET, CONVINCE, VALUE, ONTAR‐
GET, TRANSCEND, TECOS, STABILITY, SAVOR, ODISSEY, OMNEON, LIXILAN, as well
as other works in process and others scheduled to start in the near future.
Our participation in clinical trials about diabetes represents a big and continual effort in the
most relevant clinical research of this important and crucial area. We believe and hope that the
abstract’s information (clinical and pedagogical) contained in this article will be suitable to
many physicians (practitioners, internists, cardiologists, endocrinologists), chemists, nurses
and others health professionals. Unfortunately, nowadays the knowledge concerning clinical
trials and it relevance for research and health is very poor not only for physicians but also for
the general population. We would like that the present book and particularly this chapter will
offer some attractive and available information for a better knowledge of diabetes mellitus and
current medical challenges.
From this particular contribution we present to the reader a conventional design of clinical
trials commonly used everywhere. Sensu lato, the primary objective is to provide better benefits
to diabetic patients by the new non commercialized drugs (phases II, III of clinical trials)
matched to ordinary ones or placebo. To reach the aim of this research it is mandatory to have
a huge financial support coming from pharmaceutical companies, with the indispensable
contribution of investigators, patients, data managers, physicians, auxiliary staff, technical
support, computer experts, nurses, etc. In summary, the following twenty items represents a
schematic example common in many clinical trials in which we participated.
4. Conventional clinical trial design
A clinical trial is intended to produce credible results answering the questions raised about a
drug or treatment without exposing patients to unnecessary risks.
It thus requires rigorous scientific methodology:
• In choosing the options in the methodology (study design, protocol, development, calcula‐
tion of sample size, statistical analysis) which are the subject of another work in this
collection.
• In conducting the trial: this is the objective of the rules of Good Clinical Practice (in research):
use of procedures that leave little room for improvisation, validated techniques, suitable
working methods, qualified staff, a paper trail documenting all steps, data that can be
verified post hoc, which are the subject of this book.
A clinical trial is a project which involves different tasks and the final quality of its conclusions
depends on the wakest link in the chain of events. Therefore, it is important to make a major
effort in ensuring the quality of each area of interest involved, i.e. quality of documents,
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medical products, monitoring, follow-up of adverse events, and the computerized data
processing. In addition, the quality of trial should be “auditable” at all times, and hence the
need for quality in archieving all documents [table3].
Screening Run-in Randomization Randomized Post-trial
V1 V2 V3 Treatment
W-3 W-2 Day 1 Phase
V4….
Day 6
Screening period
Single-blind placebo run-in X X
Double-blind Treatment
period X X
TRIAL PROCEDURES
XObtain informed consent.
Inclusion/exclusion criteria
Medical history X
Weight X X X X
Physical examination
12-lead electrocardiogram
(ECG) X X
Adverse event monitoring X X X
Vital signs (pulse, rate and
blood pressure (measured
duplicate)
X X X X
INSTRUCTIONS/
COUNSELING
Diet and exercise
Dispense glucose meter
Introduction on dose
recording
OTHER MONITORING
TEST
CENTRAL LABORATORY
TESTS
Hematology X X X X
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Screening Run-in Randomization Randomized Post-trial
V1 V2 V3 Treatment
W-3 W-2 Day 1 Phase
V4….
Day 6
Chemistry panel X X X
Lipid Panel
X X X XFasting plasma Glucose
(FPG)
Hemoglobin A1c (A1c) X X X
Urinalysis X
STUDY MEDICATION
Dispense single-blind X X
Placebo medication X
Medication compliance X X X
V1: visit 1; V2: visit 2, W-3: week 3; W-2: week 2; FPG: fasting plasma glucose.
Table 3. Conventional Model of Trial Flowchart
1. PRINCIPLES
1.1. Declaration of principle
1.2. Organization charts
1.3. Definitions of function
1.4. Writing, management and revising procedures
1.5. Principles of planning studies
2. DOCUMENTS
2.1. Investigator’s brochure
2.2. Protocol* (standard plan, approved cycle, amendments)
2.3. Case report forms* (standard pages, approval channel)
2.4. Operations manual
2.5. Study report
3. PROTECTION OF PERSONS*
3.1. Submission of project to a committee
3.2. Writing the documents to obtain consent
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4. MONITORING*
4.1. Initial visit(s)
4.2. Meeting to set up project
4.3. Intermediate visits
4.4. Final visit
4.5. Phone contacts
5. SERIOUS ADVERSE EVENTS
5.1. Definition of serious adverse events*
5.2. Collection, documentation of cases and follow-up
5.3. Reporting*
5.4. Causal relationship
5.5. Corrective measures
5.6. Crisis management
6. THE STUDY DRUG
6.1. Obtaining a standard drug (reference therapy)
6.2. Double-blind methodology
6.3. Jury of resemblance
6.4. Packaging*
6.5. Randomization list*
6.6. Labelling*
6.7. Release of finished product (pharmaceutical and for use)*
6.8. Dispatch – Reception*
6.9. Expiry date*
6.10. Drug accountability
6.11. Dispensing
6.12. Destruction
7. DATA
7.1. Progression cycle of CRFs
7.2. Deferred correction of data*
7.3. Coding
7.4. Computer entry of data
7.5. Test to validate data
7.6. Comprising a data base
7.7. Safeguards and protection
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7.8. Computer systems (validation, documentation, use, security)
7.9. Statistical analysis
8. AUDIT AND INSPECTION
8.1. Audit of a study site
8.2. Audit of a study file
8.3. Systems audit
8.4. Preparation for inspection
9. LABORATORY VALUES
9.1. List of compulsory test
9.2. Quality control of assays
9.3. Centralized laboratory
10. DEVELOMENT
10.1. Designing a development plan
10.2. Monitoring a development plan
10.3. Coordination of a multicenter trial
10.4. Termination of a study center’s participation
10.5. Termination of a trial
10.6. Termination of a product development
11. REGULATORY AFFAIRS
11.1. Declaration or request for authorization of a trial*
11.2. Relations with the competent authorities
11.3. Submission for registration
11.4. Insurance*
11.5. Import / export of drugs for clinical trials
11.6. Periodic reports
12. MISCELLANEOUS
12.1. Monitoring training programs
12.2. Trial with no direct individual benefit
12.3. Relations with sub-contractors
12.4. Corrective measures in case a document is lost
12.5. Publication
12.6. Abbreviations
12.7. Definitions
12.8. Archieving*
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The procedures for the most part can be written by referring to the following plan.
1. Introduction
‒ Title of procedure and name of company
‒ Objetive (summary in a few lines)
‒ Other procedures simultaneously involved
‒ Personnel involved
‒ Date and number of ongoing version with the wording: “replaces previous version of…”
‒ Date of application
‒ Name of person responsible who approved this version.
2. Responsibilities: “Who?”
‒ Status of persons(s) responsible for carrying out each task stipulated in the procedure (by job title and not byname)
‒ Status of person responsible for seeing that a procedure was carried out.
3. Operations
‒ What?
Definition of the task
Where does the operation begin and end?
‒ Where?
In-house or on-site; parent company or subsidiary?
‒ When?
Start: “as soon as…” (receipt of a document…)
End: minimum, maximum duration
Chronological flow-chart of events
‒ How?
Systematic description of steps and methods to be used (equipment, personnel, documents)
Options, or variations planned (specify circumstances)
Unplanned: How and whom to refer to?
4. Verification of tasks performed
‒ One or more checklist (dated and signed)
‒ Model and circulation of report or written note
‒ Distribution list
‒ Measures to be taken when a check reveals non-compliance
5. History
‒ Dates of validity of different versions and a very succinct presentation of the reasons for the revision (one ortwo lines per version)
CORE PROTOCOL
1. Objectives and hypotheses
‒ Primary
‒ Secondary
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2. Study Endpoints: Primary, Key secondary endpoints.
3. Evidence of a personally signed and dated informed consent document indicating that the patient has been
well informed about all aspects of the study.
4. Subject/patients:
4.1. Inclusion Criteria. Subject eligibility should be reviewed and documented by an appropriate qualified
scientific study team before inclusion in the trial.
4.2. Exclusion Criteria.
5. Trial Design and Duration
6. Pre-randomization visit.
6.1. Randomization visit. Following completion of the run-in period, subjects will be randomized for active
drug and in some cases for placebo. The goal for blood glucose, glycated
6.2. hemoglobin or other biological parameters has been established by any protocol submitted for
investigation. For example, group 1 (drugs), group 2 (drugs or placebo).
7. Trial Visits. General information. Informed Consent
8. Follow-up of subjects.
9. Drug supplies.
These items include formulation and packaging, preparation and dispensing, administration, doses
adjustments, drug storage, and accountability.
10. Study Procedures.
The specific procedures, including laboratory test to be performed at all study visits. Blood draw must be
taken in the morning before 12.00 p.m.; ECG, and others parameters, and, in some cases, X-Ray, or other
diagnostic imaging procedures. It must be taken in the same day in order to offer more facilities to patients.
11. Data Collection.
The case report forms to be used are designed to collect an appropriate amount of data necessary for the
study.
12. Administrative and Regulatory Details.
13. Analysis of the End-point.
14. Quality Control.
15. Committees.
The Coordinating Office and investigators will follow the principles of Good Clinical Practice. According
with law, the trial information will be recorded in all electronic or papers forms and keep it during 10-15
years after the end of the study.
. The Committee structure is very similar from one trial to another. The members of the committees will be
detailed at the end of the publication, and also an appendix for acknowledgments will be provided
On the other side, the members of the Data Monitoring Committee are not investigators of the trial. A
National Coordinator for each country is desirable. The Steering Committee is responsible for agreeing the
protocol, any change to the protocol and for the general running of the trial. The monitoring and statistical
Committee (Data Monitoring Committee) will be responsible for quality control of the data, monitoring
recruitment and other important aspects of the investigation.
16. Data analysis / Statistical Methods. Steering Committee, Scientific Committee.
17. Ethical aspects.
Ethical conduct of the study.
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Subject information and consent.
Subject recruitment.
18. Definition of the end of trial.
19. Periodical audit.
During the study frequent external audit to the data and investigators will be done.
5. Diabetes mellitus a medical challenge
Type 2 Diabetes Mellitus (DM) accounts for more than 90% of all diabetes. This disorder is a
worldwide epidemic affecting an estimate of 366 million adults aged 20-79 years, according to
data from 2011. The prevalence of this metabolic disorder in adult population is expected to
go from 8.3% to an estimate of 9.9% by 2030, resulting in an increase in the number of people
with diabetes worldwide up to 552 million.
Unfortunately, many people are unaware that they have diabetes. The figures reveal that over
six million Americans are undiagnosed. The proportion is very similar in other Western
countries. The disease is commonly discovered when the typical symptoms, previously
mentioned, are developed and high blood sugar levels are found, defined as a daytime level
greater than 200 milligrams per deciliter or a fasting level greater than 120 milligrams per
deciliter. In some cases oral glucose tolerance test is required for undiagnosed people.
The relationship between glycemia and the risk of microvascular disease has been well-
established. The results of the Diabetes Control and Complications Trial (DCCT), the United
Kingdom Prospective Diabetes Study (UKPDS) [7], and the Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) Trial [8], demon‐
strated that patients with DM treated to lower glycemic targets have reduced rates of micro‐
vascular complications (e.g., retinopathy and nephropathy). However, results of more recent
trials including ADVANCE, the Action to Control Cardiovascular Risk in Diabetes (ACCORD),
and Veterans Affairs Diabetes Trial (VADT) [9] aimed for an A1c <6.0, and ADVANCE aimed
for an A1c<6.5%. These and other data have more recently led to a movement away from
blanket prescriptive targets for A1C (e.g. <6.5% or <7%) and to the growing consensus among
diabetes experts that glycemic targets and glucose-lowering therapies should be individual‐
ized. Age, weight, and comorbidities such as established cardiovascular disease, and kidney
or liver disease are among the patient’s factors that should be considered by physicians, nurses,
family, and others. Diet, exercise, and education remain the main stay of treatment for diabetic
patients in order to avoid serious complications [10]. In addition, there are several classes of
oral antihyperglycemic agents (AHA) available for use as monotherapy or as combination
therapy, including the dipeptidylpeptidase (DPP-4) inhibitor class, which is administered
either once or twice daily [11, 12, 13].
In general, medication adherence in chronic diseases, such as diabetes may be low, ranging
from 36% to 93%. Side effects associated with oral antihyperglycemic agents therapies,
including hypoglycemia, (sulfonylureas, meglitinides, insulin), weight gain, (sulfonylureas,
meglitinides, insulin, hypersensitivity reactions, thiazolidinediones) and gastrointestinal
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intolerance, nausea, vomiting (metformin, alpha-glucosidase inhibitors) are common patient-
reported reasons for poor medication adherence. Many studies have demonstrated that
adherence to antihyperglycemic agents therapy is related to the number of pills prescribed:
several studies have reported that, when patients were prescribed multiple drugs to treat
diabetes, adherence significantly decreased, with reductions ranging from 15% to 54%. A
prospective study showed a mean adherence of 79% for a triple-daily regimen, 65% for a twice-
daily regimen, and 38% for a thrice-daily regimen. Some data from osteoporosis therapies
indicate that, compared to a once-daily regimen, a once-weekly treatment can increase
medication adherence and compliance. Therefore, a once-weekly oral AHA therapy might
improve treatment adherence in many patients with these metabolic disorders.
6. Epidemiology and social relevance of diabetes
It’s well established that diabetes mellitus is a serious health problem in the worldwide
population and the most frequent metabolic disease, but, it is hard to know the real incidence
in the general population. There are several causes to hold up the adequate epidemiological
knowledge: a) the number of studies is limited and difficult to compare among them; b) in
many patients diagnosis of DM is not established mostly in older people with very poor
symptoms because of the absence of the conventional common disorders: polyuria, polydipsia,
polyphagia, weight loss, and asthenia; c) unfortunately, in several cases the diagnosis of
diabetes is not reported in the death certificate.
The prevalence in the European countries varies between 2% and 19.5% per 100.000 inhabi‐
tants/year; but the incidence of diabetes increases with age and other factors such as more
expectancy life, obesity, increase of glucose intake, and a better and early detection of the
disease. Another important feature of the disease is it chronic and progressive character that
need treatment for life, acute and chronic complications, and high morbidity and mortality
rate. Unfortunately, the current trend towards the increasing incidence worldwide is a reality;
with this preface diabetes will be a leading cause of clinical problems for the foreseeable future.
We must not forget that DM includes a group of common metabolic disorders characterized
by the presence of hyperglycemia usually followed by glycosuria. There is a number of types
of diabetes related to a complex interaction between genetic factors, environmental influence,
and lifestyle of patients. The consequences of the metabolic dysregulation secondary to this
disorder lead to changes in different organ systems and affect the health and future of many
patients. For example, this disease is the leading cause of end-stage renal disease, lower
extremity amputations, adult blindness, and chronic heart failure. The therapeutic procedures
are aimed at controlling diabetes; in other words, glycemic < 100 mg/dl, negative glycosuria
and glycated hemoglobin < 6%.
All patients must be put on an appropriate diet personally designed to help them to reach and
maintain normal body weight and to restrict their intake of carbohydrates and fats. They must
be encouraged to exercise daily (at least 30 minutes walking), which improves the movement
of glucose into muscle cells and blunts the rise in blood glucose that follows carbohydrate
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ingestion. In all cases, the objective of diabetes treatment is to keep the level of blood sugar
within normal values (90-100 mg/dl) as well as to reduce metabolic complications, such as
diabetic ketoacidosis, hypoglycemia, hyperosmolar coma, or lactic acidosis, and late compli‐
cations such as circulatory abnormalities, nephropathy, neuropathy, foot ulcers, frequent
infections, and retinopathy (retinal changes leading to blindness).
Recent researches into the area of treatment include pancreas transplantation and implantable
mechanical insulin infusion system, new medication, as oral hypoglycemic agents, different
modalities of insulin, and recent monoclonal antibodies given by intradermal injection way.
From another point of view, it’s well known that some clinical trials have demonstrated how
angiotensin – converting enzyme (ACE) inhibitors decrease mortality for stroke, myocardial
infarction, and other heart problems in patients with cardiovascular disease or high risk
diabetes. Nevertheless, up to 20% of patients –mostly women-are unable to tolerate captopril,
enalapril, ramipril or others ACE drugs mainly due to persistent and improductive cough, or
even other side effects such as hypotension, renal dysfunction or angioneurotic edema,
according to our personal experience [14, 15]. The Action in Diabetes and Vascular Disease:
preterAx and DiamicroN Controlled Evaluation (ADVANCE) Trial, using perindopril combined
with gliclazide was designed to assess outcome of macrovascular and microvascular disease
on diabetic patients [15]. Ramipril did not affect heart failure events in low-risk patients
according to the findings reported in the DREAM Study [16]. It’s possible to believe that when
the absolute risk of heart failure is low, angiotensin-converting enzyme inhibitors and
angiotensin-receptor blockers are not able to reduce the incidence of heart failure. Myocardial
infarction rate was lower in TRASCEND study compared to HOPE trial. It is possibly due to
that patients included in the TRASCEND study were at lower risk compared with those
admitted in HOPE (Heart Outcomes Prevention Evaluation) Study Ongoing Trial [17]; the
population of women was about 40% in the TRASCEND study while only 2% was reported
in ONTARGET trial, and other previous studies of ACE inhibitors.
It is also important to realize, according to numerous clinical experiences and data from
TRASCEND study, that telmisartan (angiotensin-receptor blockers) could be regarded as a
potential treatment for patients with vascular disease or high-risk diabetes when the patients
are unable to tolerate antihypertensive drugs as ACE inhibitors.
Concerning hypertension and based on data from many large-scale clinical trials, international
guidelines recommend two drugs with subsequent complementary mechanisms of action to
control BP in most patients, with initial combination therapy when Systolic Blood Pressure
(SBP) is 150 mmHg or Diastolic Blood Pressure (DBP) is > 100 mmHg above target [18, 19].
These guidelines also favour the use of a fixed dose combination for the clinical practice [20].
From the clinical point of view, it is significant to understand the strong pathophysiological
relationship between diabetes and hypertension. The latter is predicted to rise dramatically
with a number of cases expected to reach 1560 million worldwide by 2025 [21]. Unfortunately,
this is coupled with low rates of BP control (target <130/80 mmHg), despite the increased use
of antihypertensive treatment. It must be emphasized an early and sustained BP control in
order to reduce the long-term burden associated with this condition. To address challenges
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for now and the future, some international guidelines recommend early treatment with agents
that have complementary mechanism of action. These combinations have benefits related to
compliance, efficacy and safety for the patients.
The difficulty in getting good metabolic and clinical control of BP in many patients, may result
in the development of acute clinical disorders or chronic complications. Physicians must keep
in mind when the patient develops acute confusional states or coma; these events could be due
to DM per se, or other pathologies developed in those patients, such as hepatic failure, renal
disease, stroke, respiratory distress, poisoning or drug overdose; the distinction between coma
secondary to inadequate level of insulin, and non diabetic disease is crucial for the prognosis
of the patients.
7. Acute metabolic complications
Patients with diabetes are susceptible to four acute metabolic complications: hypoglycemia,
ketoacidosis, hyperosmolar and lactic acidosis. All of them can result in coma. The two first
are complications of IDDM, while the other two are usually developed in the setting of
NIDDM. These clinical situations must be considered completely different from severe
disorders that occur not related to DM per se such as stroke, acute heart failure, hepatic
dysfunction, in others words: coma in diabetic patients is completely different for diabetic coma.
Unfortunately, a lot of patients developed coma situations despite the treatments available,
generally caused by incorrect dose, or medication missed dose. This is the relevant point to
consider other possibilities, and the way is clinical trial.
Diabetic ketoacidosis. It is often caused by cessation of insulin administration but it may result
from physical (infection, surgery, traumatism) or emotional stress despite continued insulin
therapy. Several complications can be present in diabetic ketoacidosis: erosive gastritis or acute
gastric dilatation manifested by pain, vomiting of blood, or weight lost, cerebral edema with
or without neurological signs or coma, increased potassium serum (cardiac arrest); myocardial
infarction, respiratory distress syndrome, or thrombosis events.
Hyperosmolar coma. This modality of acute diabetes complication is usually due to NIDDM. It
is characterized by a profound dehydration resulting from a sustained hyperglycemic diuresis
by situations in which the patient is unable to drink enough water to keep up normal urinary
excretion of detritus. This situation commonly occurs in elderly patients often living alone or
in a nursing home. They develop stroke or bacterial infection that worsens adequate water
intake. Hyperosmolar coma can also be caused by peritoneal dialysis or hemodialysis, the use
of osmotic agents such as manitol and urea. Clinically, patients show extreme hyperglycemia,
hyperosmolality and central nervous system disorders (seizure activity, transient stroke,
hemiplegia or clouded sensorium and coma). Pneumonia, gram-negative sepsis or others
infections are also very common. Bleeding probably caused by disseminated intravascular
coagulation, acute pancreatitis and widespread thrombosis is usually found at necropsy.
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Lactic acidosis. It is a serious clinical finding that can occur because of an increase in endogenous
lactic acid, the final step of the carbohydrate metabolism. That causes profound effects on the
respiratory, cardiac and nervous systems. The blood pH drop suddenly and is accompanied
by an increase in respiratory ventilation (Adolph Kussmaul, 1822-1902), depression of cardiac
contractility, pulmonary edema and altered central nervous system function manifested with
headache, lethargy, stupor, or in such patients even coma. The prognosis is very bad and most
of the patients die soon.
8. Late complications
Diabetic patients are susceptible to developing several complications responsible for morbidity
and early mortality; some of them do not present problems, whereas in others, complications
appear early, usually after the appearance of the hyperglycemic symptoms developed between
15 and 20 years after the onset of the disease [table 4]. The clinical findings showed the
following circulatory abnormalities: atherosclerosis, coronary artery disease, stroke, heart
failure, peripheral vascular disease and left ventricular failure.
Microvascular Complications
Ocular disease
Retinopathy
Proliferative
Nonproliferative
Neuropathy
Mono-and polyneuropathy
Nephropathy
Macrovascular complications
Coronary artery disease
Peripheral vascular disease
Stroke
Others
Infections
Dermatology problems
Genitourinary (sexual dysfunction)
Cataracts
Psychological disorders
Glaucoma
Table 4. Late complications developed in diabetic patients
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8.1. Diabetic retinopathy
Is a relevant cause of blindness; however a high number of diabetic patients never lose the
vision. When the occlusion of retinal capillaries occurs, it results in a subsequent formation of
saccular and fusiform aneurysm and arteriovenous shunt. Hemorrhages into the inner retinal
surface are dot-shaped; conversely, bleeding into the superficial larger nerve fiber produces
flame-shaped, blot-shaped or linear lesions. Cotton-wool spots can be observed by angiogra‐
phy, and sudden increase of the number of these lesions has an ominous prognostic sign and
is the beginning of rapid progress of retinopathy. Hard exudates are common findings and are
probably related to leakage of protein and lipids from damaged capillaries. The lesions must
be summarized into two categories: simple (microaneurysms, dilated veins, hard exudates,
arteriovenous shunts, hemorrhage, cotton-wool spots, increased capillary permeability and
capillary closure, and dilation) and proliferative: new vessels, vitreous hemorrhage, retinitis
proliferans (scar) and retinal detachment.
8.2. Renal disease
Despite the worldwide importance of diabetic nephropathy as a cause of mortality and
morbidity, many questions still remain about treatment aimed at delaying its harmful effects
[22, 23]. So far, there is little scientific evidence to support strict glycemic control at this stage,
although common sense dictates that wild swings of control should be avoided. Protein
restriction may have a role but the studies to support this have not been forthcoming.
9. Circulatory changes
We recognize hypertension and DM as common disorders, but there is much evidence to
suggest that the two occur together more frequently than by chance. Development of hyper‐
tension greatly worsens the prognosis of diabetic patients. Raised BP accelerates the progress
of diabetic nephropathy, and possibly retinopathy, while the harmful cardiovascular effects
of the two disorders are at least additional. There are a number of reasons why hypertension
and diabetes may be associated, and these are discussed in this contribution.
Life expectancy is reduced in diabetic patients, both insulin-dependent (IDDM) and non-
insulin dependent (NIDDM), and the leading causes of death are cardiovascular complica‐
tions. The excess mortality cannot be explained by the diabetic state per se. Based on the
Whitehall study of more than 17.000 civil servants followed for 15 years, Jarrett and Shipley
suggested that diabetes and cardiovascular disease may not be causally linked at all but might
rather share a common, possibly genetic antecedent. Among the known risk factors for
cardiovascular disease in diabetes, hypertension has attracted much interest. The prevalence
of hypertension is increased in diabetic patients, IDDM and NIDDM, and hypertension is
known to be a powerful risk factor for cardiovascular disease in diabetes, insulin treated or
not.
It’s well known that hypertension has also a consistent relation to coronary heart disease and
other risk factors which are not only found by the presence of proteinuria. Furthermore, the
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clinical significance of hypertension as an important risk factor was recently strongly sup‐
ported by two independent studies on IDDM patients, demonstrating an improved survival
rate in the decade following the introduction of efficient antihypertensive drugs.
Hypertension is a community problem everywhere with hazardous solution. It is the major
risk factor for development and progression of the disease in non-diabetic and diabetic chronic
kidney disease. About one billion people worldwide have high BP (defined as > 140/90 mmHg),
but the number is higher considering the present criteria of >130/80 mmHg, and it is expected
to increase up to 1.56 billion patients by 2025. The predicted prevalence of hypertension will
increase by 24 per cent in developed countries.
Hypertension control rate, defined as BP level < 130/80 mmHg, is substantially lower in
patients with CKD, particularly in those with diabetes and chronic renal failure. This is
illustrated by the National Kidney Foundation’s (USA) Kidney Early Evaluation Program
(KEEP), a US-based health screening program for individuals at a high risk for kidney disease.
Hypertension is the most prevalent cardiovascular disease in the world and a major public
health issue. Cardiovascular disease is the leading cause of mortality worldwide and is
expected to increase with the general ageing of the world’s population. The goal of anti-
hypertensive therapy is to reduce the incidence of blood pressure-related morbid events and
cardiovascular mortality.
It is well established that heart is an important target organ in hypertension. Continuous high
BP level is associated with myocardial problems, such as left ventricular hypertrophy and
increases the burden of coronary artery disease (CAD). These forms of damage may result in
congestive heart failure, CAD manifestations, arrhythmias and sudden cardiac death. The
event rates of cardiovascular disease in Japan, for example, differ from those in Europe and
the United States. Mortality from CAD in the Japanese country is one-third that of the United
States, and mortality from cerebrovascular disease is 1.5 times higher in Japan than that
reported in the United States. Hypertension is the most common cause of disease and is even
more prevalent in the Japanese population than in the Western countries. The percentage of
cerebral bleeding is two or three times greater than in Caucasian people from Europe and the
United States, and cerebral infarction is mostly caused by lacunar type ischemic stroke owing
to hypertensive small vessel disease. The incidence of athero-thrombotic infarction or cardio-
embolic infarction is currently increasing in Japan, and the dominant pathogenetic factor for
stroke is changing from small arterial disease to large arterial disease in Japanese hypertensive
patients. These differences may be partly explained by differences in the lifestyle of Japanese
and Western populations, which are reflected in body mass index (mean BMI: 23.25 and 28-30
kg/m2, respectively). However, most of mortality-morbidity trials have been carried out in the
Western countries, in which none or only a minority of East Asian patients were included.
Owing to the scarcity of large-scale trials in East Asian people, it remains to be determined
whether the results from similar clinical trials in Western societies are internationally appli‐
cable to East Asian races or the Japanese population, or whether genetic background can cause
different pharmacokinetic and pharmacodynamic responses to the same drug.
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There is a clear and substantial evidence in juvenile onset IDDM that strict BP control by
reducing and maintaining levels under 130/80 mmHg or a mean arterial pressure of 105 mmHg
remains the only effective treatment for the physician to try to slow the development of end
stage renal failure and the need for renal support. In practical terms, the use of a combination
of drugs including diuretics will be often required. The newer classes of drugs such as ACE
inhibitor or calcium channel blockers have a clear advantage in their side-effect profile over
betablockers in diabetics, because they are safer and better tolerated. The primary goal remains
effective in BP control and often beta-blockers may need to be added to the regime to achieve
this.
In patients with IDDM aged older than sixty and in diabetics with nephropathy who are non-
insulin dependent, there is no definitive scientific evidence that prognosis is improved and
that the progression to end stage disease is slowed after antihypertensive treatment. It is
reasonable for the physician to assume that aggressive treatment of BP in this group is justified
from data of several studies in younger patients. A crucial question remains about the degree
of BP reduction required and in particular whether it is necessary or indeed harmful to
aggressively reduce systolic BP in this group. Accurate long-term clinical trials with measure‐
ment of cardiovascular end points as well as the slowing of GFR decline and reduction of
proteinuria need to be carried out. Indeed, it is important to reach normal BP levels especially
on the stage of incipient nephropathy in order to obtain better therapeutic results in patients.
Large scale, long-term multicenter studies in both IDDM and NIDDM patients with protei‐
nuria will be required to give a clear answer to the question of whether there is a selective
benefit of the ACE inhibitor group over a suitable hypotensive agent such as a calcium channel
blockers. So far, there is some evidence that ACE inhibitors used in the evolution of nephrop‐
athy or when employed later in combination with diuretics are effective in reducing protein
excretion which may be separate from their BP lowering capacities. These data, make them a
reasonable choice in the antihypertensive regime of diabetics with nephropathy. This property
to reduce proteinuria without reducing BP has not been shown with any other antihyperten‐
sive agents and until and unless such evidence is forthcoming, the careful use of ACE inhibitors
in combination with diuretics can be recommended in diabetic nephropathy. As many of these
patients will have occult or manifest cardiovascular dysfunction, this approach may be
beneficial also in improving cardiac performance. Future studies, especially in non insulin-
dependent patients should evaluate the potential benefit of reducing morbidity and mortality
from cardiovascular disease with the newer antihypertensive drugs, such as ARA II.
Coexisting hypertension and diabetes act as additive risk factors to accelerate vascular
complications. The incidence of coronary and cerebral vascular diseases is much higher in
hypertensive than in normotensive diabetic patients. Mortality rates in diabetic patients with
systolic BP exceeding 160 mmHg is four times higher than that of other diabetic individuals.
Whereas antihypertensive therapy has been clearly shown to retard deterioration of renal
function and urinary albumin excretion, evidence that pharmacological control of BP reduces
overall mortality in the diabetic population without overt nephropathy is strikingly lacking.
Thus, current recommendations for drug intervention in diabetics with hypertension rely on
data derived from the general hypertensive population. Specific adjustments in drug selection
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and dosage need to be made for drug effects which might be of particular significance in the
diabetic patient. Nevertheless, a recent alarming retrospective study from the Joslin Clinic
demonstrated that antihypertensive treatment is associated with a marked increase in
cardiovascular mortality in diabetic hypertensive patients. The most obvious implication of
this finding is the need for large scale prospective studies in diabetic hypertensive individuals
to assess the risks and benefits in treating hypertension in this population. Some of the newest
strategies for BP control must be examined and compared with these retrospective findings.
Until further information becomes available, much attention should be given to careful drug
selection, therapy monitoring, and judicious and continuous assessment of coexisting risk
factors in the course of treatment of high BP in diabetes.
10. Etiology of chronic diabetes complications
The cause of diabetic complications is still unknown and probably multifactorial. Chronic
complications of DM affect many organ systems and are responsible for the majority of
morbidity and mortality. Special attention must be given to the metabolic conversion of glucose
to sorbitol. This one is implicated in the pathogenesis of neuropathy, retinopathy, aortic
disease, nephropathy and lens damage (cataracts). Another mechanism of possible pathoge‐
netic relevance is glycation of proteins. The effect of glycation on hemoglobin is well known;
in addition, other proteins are altered by the same mechanism such as plasma albumin, fibrin,
collagen, lipoproteins, and low protein. Retinopathy, nephropathy and neuropathy are
considered common disorders of microvascular complications; and stroke, gangrene, and
myocardial infarction for macrovascular complications [table 4].
11. Can diabetic complications be prevented?
This is an important and fascinating question strongly related with the patient prognosis.
Hyperglycemia or other aspects of the abnormal metabolism of diabetes are responsible for
the development of complications; additional factors, which maybe genetic, have also a
pathogenic influence. The clinical practice shows the mistery; how diabetic patients suffering
for decades from poor control are free of late complications; however typical complications
can be found at the time of diabetes diagnosis, even in the absence of fasting hyperglycemia.
Intensive therapy for all diabetic patients with strict dietary control is essential. The role of the
family doctor, specialist and other professionals –nurses, nutritionists, auxiliary persons, etc-,
are very important for these particular patients.
12. Miscellaneous findings on diabetes
Because diabetes affects almost every body systems, the patients can develop several symp‐
toms and complications. The chapter of Infections is large. In some cases this finding may not
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occur more frequently than in non diabetic population, but it seem to be more severe probably
because in diabetic patients leukocyte function is impaired and subsequently accompanied by
poor control. Also this population is particularly prone to four unusual infections with strong
relationship with diabetes –focus on skin, urinary tract, lungs, and bloodstream. Malignant
external otitis, usually due to Pseudomonas aeruginosa tends to appear in older population and
is characterized by severe pain in the ear, fever, and leukocytosis. The facial nerve becomes
paralyzed in 50% of the cases, but other crucial nerves can be involved. Emphysematous
cholecystitis tends to affect diabetic men and diagnosis is established when gas is seen in the
gallbladder wall or during non invasive imaging examination.
Hypertriglyceridemia is common in diabetics and is related to overproduction of VLDL (Very
Low Density Lipoprotein) in the liver and to a defect of metabolization on the peripheral tissues.
The latter is due to a deficiency of lipoprotein lipase, an insulin-dependent-enzyme. It is
important to know that some patients have high level of lipids profile even when diabetic
disease is controlled; probably these cases have a primary familial hyperlipoproteinemia, a
circumstance independent of DM. Of course, these patients must be treated for lipids disorder
–hypertriglyceridemia and lipids hypercholesterolemia with HMG-CoA reductase inhibitors
such as lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin, as mode of
action that reduces cholesterol synthesis and increases LDL receptors; ezetimibe reduces the
absorption of lipids from diet at the intestinal level; and fibric acid derivatives –↓  LPD and
tryglyceride, hydrolysis, VLDL synthesis, ↑  LDL catabolism. Patients can also suffer from a
variety of skin lesions: necrobiosis lipoidica diabeticorum, candida albicans, vaginal monilia‐
sis, in women, hypertrophy of fat, bullosis diabeticorum, diabetic dermopathy, atrophy of
adipose tissue, Dupuytren’s contractures, and schleroderma. Additional illnesses such as the
prevalence of eating disorders can be seen particularly in young women.
13. Physical examinations of diabetic patients
Either complete physical examination or brief physical examination will be performed at the
time points specified in the Time and Events Table.
The complete physical examination will include evaluation of the following organ or body
systems:
• Skin (including injection site)
• Head, eyes, ears, nose, and throat
• Thyroid
• Respiratory system
• CV system, BP
• Abdomen (liver, spleen)
• Lymph nodes (neck, axilas, inguinal)
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• Central nervous system
• Extremities
The brief physical examination will include evaluation of the following organ or body systems:
• Skin (including injection site)
• Respiratory system
• CV system
• Abdomen (liver, spleen)
• Central nervous system
14. Conclusions
The term of diabetes mellitus includes a group of some metabolic disorders characterized by
hyperglycemia with secondary damage to multiple organ systems such as end–stage renal
disease, lower extremities amputations, and adult blindness. The way to ameliorate this crucial
situation is to obtain better drugs for an early treatment of the patients. The clinical trials, is
so far, the best procedure to offer more efficient treatments to the increasing diabetic popula‐
tion, thanks to the procedures of clinical trials [24, 25].
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